Drugs / NS-050/NCNP-03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06053814 | Sep 2024 → Mar 2028 expected | Duchenne muscular dystrophy | NS Pharma, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-06 | Nippon Shinyaku Co., Ltd. | デュシェンヌ型筋ジストロフィー治療剤「NS-050/NCNP-03」米国における希少小児疾患指定受理のお知らせ nippon-shinyaku.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NS-050/NCNP-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06053814 ↗ |
| Route | Intravenous | “Participants will be randomized and receive NS-050/NCNP-03 intravenous (IV) infusions once weekly” NCT06053814 ↗ |